1 active not recruiting, 1 completed, 1 no longer available, 1 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Elicio Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer ELI-002 7P, Tislelizumab, mFOLFIRINOX - Pancreatic Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2026-06-22 | 2026-10-28 |
| A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors ELI-002 7P - Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | Elicio Therapeutics | 158 | 2023-04-14 | 2026-07-10 |
| A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors ELI-002 2P - Minimal Residual Disease, KRAS G12D | Phase 1 | Completed | Elicio Therapeutics | 25 | 2021-10-04 | 2025-09-05 |
| Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma ELI-002 7P - Pancreatic Ductal Adenocarcinoma, KRAS G12D | No longer available | Elicio Therapeutics | 2026-07-10 |
Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Rectal Neoplasms (2) · Bile Duct Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Gallbladder Neoplasms (1) · Neoplasm, Residual (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
tislelizumab (1)
United States (3)
Kevin Soares, MD (1)